Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Assay in which an enzyme present is a label

Subclass of:

435 - Chemistry: molecular biology and microbiology

435004000 - MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP

435700100 - Involving antigen-antibody binding, specific binding protein assay or specific ligand-receptor binding assay

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
435700920 Heterogeneous or solid phase assay system (e.g., ELISA, etc.) 977
435700910 Enzyme produces product which is part of another reaction system (e.g., cyclic reaction, cascade reaction, etc.) 5
20090221007DIAGNOSIS, PREVENTION AND TREATMENT OF CROHN'S DISEASE USING THE OMPC ANTIGEN - The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.09-03-2009
20090221006DIAGNOSIS, PREVENTION AND TREATMENT OF CROHN'S DISEASE USING THE OMPC ANTIGEN - The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.09-03-2009
20100255512ANALYTICAL STRIP AND DETECTING METHOD USING THE SAME - An analytical strip and a detecting method using the analytical strip are provided. The analytical strip includes a substrate having a channel thereon. The channel has a first region, a second region and a third region, which are connected sequentially. A first antibody is localized in the first region. A saccharide and a peroxidase are localized in the first or second region. A second antibody for recognizing a different epitope of an identical antigen with the first antibody is immobilized in the second region. An optical substrate and a substrate reagent including a saccharide oxidase are localized in the third region.10-07-2010
20110236911Precipitating Substrate for Bio-Layer Interferometry - Improved apparatus, compositions, and methods for carrying out interferometry-based assays for detecting analytes in a sample through the use of a precipitating substrate to enhance an interferometry binding signal, and kits useful for carrying out these assays. Methods comprise providing an optical assembly comprising an optical element with a transparent material and adapted for coupling to a light source via a fiber, a first reflective surface and a second reflecting surface having a first analyte-binding molecule and separated from said first surface by a distance, d, exposing said optical element to a sample comprising said analyte, a second analyte binding molecule, and a precipitating substrate; and detecting a change in thickness at said first reflective surface thereby detecting said analyte in said sample. Kits include reagents for derivatizing assay components along with packaging and instructions for use.09-29-2011
20090298101Blood C5a Levels as an Indicator of Rhinoconjunctivitis Severity - The present invention provides methods of determining the severity of rhinoconjunctivitis in a patient by determining the levels of C5a or C5a-desArg in the patient's blood, plasma or serum.12-03-2009
Entries
DocumentTitleDate
20130045488BENZOCYANINE COMPOUNDS - Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.02-21-2013
20100159483ARTICLE FOR ASSAYING TARGET, COMPRISING SOLID SURFACE ON WHICH FIRST BINDING MEMBER, BLOCKING MATERIAL, AND SECOND BINDING MEMBER ARE IMMOBILIZED, AND USE THEREOF - Disclosed are an article for assaying a target, wherein the article includes a solid surface on which a first binding member, a blocking material, and a second binding member are immobilized, a method of manufacturing the article, and a method of detecting a target using the article.06-24-2010
20100009388DIFFERENTIAL DETECTION OF MULTIMERIC AND MONOMERIC FORMS OF MULTIMER-FORMING POLYPEPTIDES - A method for differentially detecting a multimeric form from a monomeric form of a multimer-forming polypeptide in a biosample includes (a) contacting the biosample to a capturing antibody recognizing an epitope on the multimer-forming polypeptide to capture the monomeric form, multimeric form or monomeric and multimeric forms; (b) contacting the monomeric form, multimeric form or monomeric and multimeric forms captured to a detecting antibody recognizing an epitope identical to or overlapped with the epitope of step (a); and (c) detecting the formation of a multimeric form-detection antibody complex.01-14-2010
20130034866MULTISIGNAL REAGENTS FOR LABELING ANALYTES - Provided is a composition comprising an analyte bound covalently or through a first binding pair to a polymer. In this composition, the analyte is less than about 2000 MW; the polymer further comprises more than one signal or first member of a second binding pair; and the analyte is not a member of the first binding pair or the second binding pair. Also provided is an assay for an analyte. The assay comprises: combining a sample suspected of containing the analyte with the above-described composition and a binding agent that binds to the analyte; and detecting the signal or the first member of the second binding pair that is bound to the binding agent. In this assay, the amount of the signal or the first member of the second binding pair bound to the binding agent is inversely proportional to the analyte in the sample. Additionally provided is a multisignal labeling reagent comprising a first polymer covalently bound to (a) a reactive group or a first member of a first binding pair, and (b) more than one digoxigenin molecule.02-07-2013
20130040314IMMUNOASSAY OF CARBOXYMETHYLARGININE - A measuring method by which carboxymethylarginine can be measured with ease and with a high degree of precision is disclosed. The measuring method is a method of measuring carboxymethylarginine in a sample. The method includes treating the sample with a pretreatment agent including urea; and measuring carboxymethyl arginine in the pretreated sample by an immunological method.02-14-2013
20130034865CENTRIFUGAL FORCE-BASED MICROFLUIDIC DEVICE FOR MULTIPLXED ANALYSIS AND DETECTION METHOD USING THE SAME - A centrifugal force-based microfluidic device for a multiplexed analysis and an analyzing method using the same are provided. The microfluidic device includes a platform and a microfluidic structure including a plurality of chambers formed within the platform and valves positioned between the chambers. The microfluidic structure includes a sample separation chamber connected to a sample injection hole and a plurality of reaction chambers accommodating two or more types of markers specifically reacting to different types of target materials, separately by type.02-07-2013
20090155817GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF - The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.06-18-2009
20100105079BIO SURFACE ACOUSTIC WAVE (SAW) RESONATOR AMPLIFICATION WITH NANOPARTICLES FOR DETECTION OF A TARGET ANALYTE - The present invention relates generally to a signal amplification method for a SAW resonator microsensor for analyzing test samples, containing target analyte including proteins and nucleic acids. The method comprising the steps: reacting the analyte in a sample with a first molecular recognition component and a second molecular recognition component linked to at least one nanoparticle; and adding an enhancement solution comprising silver ions and/or gold ions, and a reducing agent, whereby the silver ions and/or gold ions are reduced to metallic silver and/or gold which is deposited onto the surface of the at least one nanoparticle; wherein the mass increase of the at least one nanoparticle is detected by a SAW sensor.04-29-2010
20100041071METHOD FOR DETERMINATION OF MOLECULAR WEIGHT OF HYALURONIC ACID - A method of measuring a molecular weight of hyaluronic acid, comprising at least reacting hyaluronic acid in a sample containing the hyaluronic acid with a hyaluronic acid-binding protein to measure an amount of the hyaluronic acid-binding protein that is bound to the hyaluronic acid in the sample or a value that reflects the amount.02-18-2010
20100021942Cell-free expression system for the detection of bacterial biofilms - Provided is a cell-free expression system and method for its use for detecting the presence of a bacterial biofilm on a surface, wherein the film comprises a) an exogenous quorum sensing protein or an exogenous nucleic acid sequence coding for a quorum sensing protein capable of selectively binding to a bacterial signaling molecule; and b) an exogenous nucleic acid sequence comprising a promoter operably linked to a nucleic acid sequence coding for a marker protein, wherein the promoter is regulated by the binding of the quorum sensing protein to the bacterial signaling molecule. Further provided is an aerosol formulation, as well as an adhesive bandage, each of which may be used for detecting the presence of a bacterial biofilm on a surface, comprising the disclosed cell free expression system and methods therefor.01-28-2010
20090042218Labeling enzyme - The present invention relates to a labeling enzyme and a method of detecting and/or quantifying a target substance using this labeling enzyme. The present invention provides a labeling enzyme that catalyzes a reaction of gelling a substrate. By measuring changes in physical properties such as the film thickness and/or refractive index of a film produced by the gelling reaction catalyzed by the labeling enzyme of the present invention, it is possible to quickly and highly sensitively detect and/or quantify a target substance while minimizing the effects of coexisting substances.02-12-2009
20130071857Biomarkers Of Gastric Cancer And Use Thereof - A set of biomarkers indicative of early gastric cancer and method of diagnosing gastric cancer at an early stage by directing the these biomarkers in a blood sample. Detection of over-expression of one or more protein biomarks in the group consisting albumin, T-kininogen I, α-2-HS glycoprotein, α-1-antitrypsin, afamin and γ-actin and/or detection of under-expression of one or more protein biomarks in the group consisting stress 70 protein, apolipoprotein A-I, apolipoprotein A-IV, transthyretin and murinoglobulin is indicative of the presence of gastric cancer.03-21-2013
20130059316PLASMONIC ELECTRICITY - The present invention relates to detection systems and methods that detect fluorescence, luminescence, chemiluminescence or phosphorescence signatures in the form of an electrical signal conducted and emitted from metallic containing surfaces. Thus, the present invention provides for detecting fluorescence digitally and directly without the need for expensive detectors.03-07-2013
20120309025METHOD OF ANALYZING HUMAN sCD14-ST - An analysis method capable of accurately measuring human sCD14-ST when using a whole blood sample is provided. In the analysis method, human sCD14-ST in a whole blood sample is analyzed within 6 hours of the collection of the sample.12-06-2012
20110014633ELECTRIC ANALYSIS METHOD - Disclosed is an analysis method comprising the steps of:01-20-2011
20110014632ASSAYS FOR CLINICAL ASSESSMENTS OF RHEUMATOID ARTHRITIS - The disclosure provides methods of detecting autoantibodies present in the serum of subjects suffering from rheumatoid arthritis. The methods use capture probes and detection probes that can bind to the antifilaggrin autoantibodies or other epitope related autoantibodies. The presence, absence, and/or amount of the autoantibody complex may be detected, wherein the presence of the complex may indicate a positive diagnosis of rheumatoid arthritis.01-20-2011
20120190047Levetiracetam Immunoassays - Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.07-26-2012
20120115166DIAGNOSTIC METHODS FOR THE DETECTION OF RISK OF NEURODEVELOPMENTAL DISORDERS - The present invention provides methods of identifying markers indicative of the risk of developing a neurodevelopmental disorder caused in part by antibody- or autoantibody-mediated damage of neural tissue, including autism spectrum disorder (ASD). The invention further provides methods of diagnosing whether an individual has a neurodevelopmental disorder, including an ASD, and methods for determining the risk that a mother's future offspring will develop an a neurodevelopmental disorder, including an ASD.05-10-2012
20090011436Dry Chemistry, Lateral Flow-Reconstituted Chromatographic Enzyme-Driven Assays - A lateral flow chromatographic assay format for the performance of rapid enzyme-driven assays is described. A combination of components necessary to elicit a specific enzyme reaction, which are either absent from the intended sample or insufficiently present therein to permit completion of the desired reaction, are predeposited as substrate in dry form together with ingredients necessary to produce a desired color upon occurrence of the desired reaction. The strip is equipped with a sample pad placed ahead of the substrate deposit in the flowstream, to which liquid sample is applied. The sample flows from the sample pad into the substrate zone where it immediately reconstitutes the dried ingredients while also intimately mixing with them and reacting with them at the fluid front. The fluid front moves rapidly into the final “read zone” wherein the color developed is read against predetermined color standards for the desired reaction. Pretreatment pads for the sample, as needed, (e.g. a lysing pad for lysing red blood cells in whole blood) are placed in front of the sample pad in the flow path as appropriate. The assay in the format of the invention is faster and easier to perform than analogous wet chemistry assays.01-08-2009
20120237950ANALYSIS CHIP, ANALYSIS SYSTEM, AND ANALYSIS METHOD - An analysis chip for quantitative analysis by using a competitive reaction is provided. The analysis chip for analyzing a target substance to be identified in a liquid sample includes a base, and a flow path formed on the base. The flow path includes an introduction portion, for introducing the liquid sample; a reaction portion, disposed at a downstream side of the introduction portion, for subjecting the liquid sample to a competitive reaction; a discharge portion, disposed at a downstream side of the reaction portion; and a blocking portion, disposed between the reaction portion and the discharge portion, for inhibiting the flow of the liquid sample from the reaction portion to the discharge portion. The reaction portion accommodates a carrier prefixed with a specific binding substance for specifically binding the target substance to be identified or a competitive substance of the target substance to be identified.09-20-2012
20110027802Methods and Kits for Separation and Detection of Proteins in Biological Samples - Methods and kits are provided for separating a mixture of proteins in a biological sample. Methods for detecting and profiling proteins in biological samples by the separation method and kits are also provided. These methods are particularly useful in assessing damage to cells such as cardiac and skeletal muscle cells and in the early clinical diagnosis of myocardial damage by detection of myofilament proteins in serum of a subject.02-03-2011
20100261199Assay for the detection of phosphorylated PTH - Antibodies for a variant of intact parathyroid hormone (PTH) or its fragments which have at position 17 the amino acid serine which is phosphorylated [p(17) PTH] and methods of producing the same. The invention further includes various immunoassay methods which use the described antibody alone or in combination with other antibodies to determine the circulating levels of p(17) intact PTH (1-84) or fragments thereof in biological fluids. Such antibodies and immunoassays can be used in conjunction with other antibodies to detect all biologically active forms of hPTH present in biological fluids.10-14-2010
20090246804Immuno gold lateral flow assay - A chromatographic specific binding assay strip device, comprising: a non-permeable platform strip; a permeable membrane testing strip positioned on top of said non-permeable platform strip, with the testing strip comprising at least one capture reagent site containing a capture reagent for at least one specific analyte, a sample receiving pad positioned on top of and at a proximal end of the non-permeable platform strip, with the sample receiving pad having contact with a proximal end of said permeable membrane testing strip, a reservoir pad positioned on top of and at a distal end of said non-permeable membrane testing strip, with the reservoir pad having contact with a proximal end of said permeable membrane test strip; a supporting strip attached to and extending from the proximal end of said non-permeable platform strip; and a conjugate pad positioned on said supporting strip, said conjugate pad comprising a semi-permeable membrane containing a colorant conjugate. The semi-permeable membrane acts as a barrier between the conjugate pad and the sample receiving pad, regulating the flow through the semi-permeable membrane and overall flow of the assay. By dipping the conjugate pad into a sample solution, there will be increased binding between the analyte in the sample and the conjugate (preferably colloidal gold), thereby giving improved results on the lateral flow assay.10-01-2009
20100196927METHOD OF DETERMINING FUNCTIONAL DEFICIENCIES IN THE COMPLEMENT SYSTEM - The present invention relates to a method of in vitro determining functional deficiencies in the lectin pathway of the complement system, the method comprises the steps of (a) diluting a mammalian sample of body fluid with a diluent comprising one or more inhibitors of the activation of the classical and the alternative pathways of the complement system; (b) activating the lectin pathway of the complement system in the sample obtained from (a); and (c) determining in the sample obtained from (b) the activation of one or more of the complement factors C3, C4, or one or more of the components of the C5-C9 complex. The invention furthermore relates to kits for use in connection with the above-mentioned method, the first kit comprises i) a first component comprising a carrier, one or more inhibitors of the classical and the alternative complement pathways and a diluent; and ii) a second component comprising one or more substances for activation of the lectin complement pathway and optionally an inert carrier. The second kit comprises a container comprising a predetermined amount of one or more inhibitors of the classical and the alternative complement pathways and a diluent, wherein the container is adapted for receiving a predetermined amount of sample, so that when the predetermined amount of sample is added, the concentration of the one or more inhibitors is an inhibitory effective concentration of the classical and alternative pathways, but not the lectin pathway.08-05-2010
20080318249Methods and reagents to increase the sensitivity of enzyme metallographic detection - A test agent includes a composite probe having at least one nanoparticle having multiple metal atoms, a directing agent, and an enzyme. The directing agent attaches the probe to a target in a test sample. The test sample and bound probe are then treated with an enzyme substrate. A method of detecting a target in a test sample includes exposing the test sample to the probe, then treating the test sample with an enhancement or development solution to deposit at least one of a fluorophore, a chromogen, or a metal.12-25-2008
20100015637PIGF-1 ASSAY AND KITS AND COMPONENTS THEREOF - The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.01-21-2010
20110091906Immuno gold lateral flow assay - A chromatographic specific binding assay strip device, comprising: a non-permeable platform strip; a permeable membrane testing strip positioned on top of said non-permeable platform strip, with the testing strip comprising at least one capture reagent site containing a capture reagent for at least one specific analyte, a sample receiving pad positioned on top of and at a proximal end of the non-permeable platform strip, with the sample receiving pad having contact with a proximal end of said permeable membrane testing strip, a reservoir pad positioned on top of and at a distal end of said non-permeable membrane testing strip, with the reservoir pad having contact with a proximal end of said permeable membrane test strip; a supporting strip attached to and extending from the proximal end of said non-permeable platform strip; and a conjugate pad positioned on said supporting strip, said conjugate pad comprising a semi-permeable membrane containing a colorant conjugate. The semi-permeable membrane acts as a barrier between the conjugate pad and the sample receiving pad, regulating the flow through the semi-permeable membrane and overall flow of the assay By dipping the conjugate pad into a sample solution, there will be increased binding between the analyte in the sample and the conjugate (preferably colloidal gold), thereby giving improved results on the lateral flow assay.04-21-2011
20110020840METHOD AND KITS FOR DETECTING ANTIBODIES AGAINST THERAPEUTIC ANTIBODIES - The invention relates to the field of immunology and immunological diagnostics. More specifically, it relates to detection of the formation of antibodies in a subject that is treated with a therapeutic antibody. Provided is A diagnostic method for determining the presence of IgG antibodies against a therapeutic antibody in a subject, comprising the steps of: a) providing a solid carrier capable of binding the constant region of IgG antibodies; b) isolating a sample from a subject to be tested for the presence of IgG antibodies against a therapeutic antibody; c) incubating said carrier with said sample under conditions suitable for immobilizing IgG antibodies on said solid carrier; d) incubating said immobilized antibodies with an antigenic fragment of said therapeutic antibody under conditions that allow for complex formation between at least part of said immobilized antibodies and said antigenic fragment, said fragment lacking a constant region and being conjugated to a detectable label; and wherein said incubation is performed in the presence of an unlabeled antigenic fragment of a non-therapeutic antibody lacking a constant region. Also provided are kits for use in such a method.01-27-2011
20110300558NANOPARTICLE FOR BIOAFFINITY ASSAYS - Thus this invention relates to a nanoparticle, useful for bioaffinity assays. The nanoparticle has a self-assembling shell built up of several protein and/or peptide subunits, which protein and/or peptide subunits can be of one or several different types, assembled in an organized manner to form the shell having an inner surface facing the inside and an outer surface facing the outside of said particle. One or several of the types of subunits have one or several first binding moieties per type of subunit with the binding moiety facing the outside of the particle for binding of any specific ligand binding protein; and the particle contains within its shell a marker and/or one or several of the types of subunits have one or several second binding moieties per type of subunit with the binding moiety facing the inside and/or the outside of the particle for binding a marker; and the marker or markers enables detection of the particle. Characteristic for the nanoparticle is that the shell of the nanoparticle is a recombinant apoferritin or an apoferritin-like particle. This invention also relates to a bioaffinity assays using the nanoparticle. This invention further relates to a kit for bioaffinity assays comprising the nanoparticle.12-08-2011
20110300557METHODS FOR PREDICTING PREGNANCY OUTCOME IN A SUBJECT BY hCG ASSAY - The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.12-08-2011
20090176252Method for the Measurement of Endocrine Substances In an Analyte - The present invention provides a method for the measurement capable of measuring an endocrine substance such as feline insulin in an analyte of an animal such as feline or the like with high accuracy, rapidity and brevity.07-09-2009
20090011435ASSAYS FOR DETECTING ANTIBODIES TO THERAPEUTICS - The disclosed invention relates to methods and devices for detecting a biologic in a test sample. In particular, the disclosed assay utilizes EPO as a target to detect endogenous anti-EPO antibodies in a sample and does not manipulate or modify the target EPO antibody.01-08-2009
20130189708SAMPLE ANALYZER AND A SAMPLE ANALYZING METHOD - Herewith disclosed is a sample analyzer comprising: a measurement section configured to perform a measurement on a sample and generate a measurement value according to the concentration of an analyte in the sample; a memory storing a calibration curve; an analysis section; an output section; and an instruction receiver. When the instruction receiver receives an instruction to perform a diluting measurement on a calibration sample, the measurement section dilutes the calibration sample by a predetermined ratio and performs a measurement on the diluted calibration sample, and the analysis section determines the concentration of the analyte in the diluted calibration sample by applying a measurement value obtained from the diluted calibration sample to the calibration curve. Information generated based on the determined concentration and the known concentration is output.07-25-2013
20100112599METHOD FOR THE COUPLED ENZYME IMMUNOCHEMICAL ASSAY OF ANALYTES BY MEANS OF ENDOGENOUS CALIBRATORS - The invention relates to a method for assaying a plurality of analytes such as e.g. metabolites and antigens in biological and other liquid samples by means of analytical elements, especially lateral-flow test strips, flow-through membrane systems (flow-through tests), wells/cavities of microtitre plates or test tubes, the method according to the invention being based on coupled enzyme and affinity reactions and being carried out by means of endogenous calibrators, i.e. endogenously produced substances, by means of which dilutions of sample matrices can be corrected (e.g. creatinine, glucose, glucose-6-phosphate, lactate, glutamate, aspartate, cholesterol, pyruvate, urea and triglycerides).05-06-2010
20100267056DIFFERENTIAL LABELLING METHOD - The invention relates to a method for differentially labelling one or more entities, together comprising distinct reactive sites. The invention further relates to an entity that has been labelled by a method according to the invention and to a diagnostic kit comprising a labelled entity and to a diagnostic kit to employ a method according to the invention.10-21-2010
20100267055ONE-STEP IMMUNOASSAYS EXHIBITING INCREASED SENSITIVITY AND SPECIFICITY - The present disclosure relates to immunoassays for detecting or quantifying at least one analyte of interest in a test sample which exhibits improved sensitivity or sensitivity and specificity compared to the immunoassay formats known in the art.10-21-2010
20100279315IMPROVED METHOD FOR PRENATAL DIAGNOSIS - The invention discloses a method of prenatal diagnosis comprising the step of isolating exosomes from an isolated fluid, wherein the exosomes are identified by biomarker detection. Furthermore, the invention discloses the isolation of exosomes from an isolated fluid and the use of a biomarker, particularly CD24 to isolate exosomes from an isolated fluid.11-04-2010
20120231475IMMUNOASSAY FOR DETERMINING THE RELEASE OF NEUROTENSIN INTO THE CIRCULATION - The invention relates to an immunodiagnostic determination method for determining the release of neurotensin into the circulation of mammals during which an immunoreactivity of the N-terminal portion of a mammal proneurotensin (PNT immunoreactivity) is selectively determined in a serum sample or plasma sample of a test mammal, this immunoreactivity not being a neurotensin or neuromedin immunoreactivity.09-13-2012
20090087865Monoclonal Antibodies to Tacrolimus and Immunoassays Methods for Tacrolimus04-02-2009
20100273189NON SEPARATION ASSAYS WITH SELECTIVE SIGNAL INHIBITORS - Methods, reagents, kits and systems are disclosed for determining an analyte in a sample, the assay method comprising forming a reaction mixture in an aqueous solution, by adding a chemiluminescent-labeled immobilized specific binding member, an activator-labeled specific binding member, a selective signal inhibiting agent, and a sample, wherein the chemiluminescent-labeled immobilized specific binding member and activator-labeled specific binding member bind to analyte present in the sample to form a binding complex, and adding to the reaction mixture a trigger solution to release a detectable chemiluminescent signal correlated to the amount of the analyte-bound binding complex present in the reaction mixture.10-28-2010
20090280507METHOD FOR MEASUREMENT OF SARS VIRUS NUCLEOCAPSID PROTEIN, REAGENT KIT FOR THE MEASUREMENT, TEST DEVICE, MONOCLONAL ANTIBODY DIRECTED AGAINST SARS VIRUS NUCLEOCAPSID PROTEIN, AND HYBRIDOMA CAPABLE OF PRODUCING THE MONOCLONAL ANTIBODY - The present invention provides a method for measuring SARS virus nucleocapsid protein (SARS-NP) using first and second antibodies both binding specifically to SARS-NP, wherein the first or second antibody is an antibody recognizing an epitope located in a region (Region C) of amino acid 283 to 422 from the N-terminus of the amino acid sequence of SARS-NP.11-12-2009
20090263834Droplet Actuator Devices and Methods for Immunoassays and Washing - Droplet actuator devices and methods for immunoassays and washing are provided. According to one embodiment, a method of providing a droplet in contact with a surface of a super paramagnetic bead with a reduced concentration of a substance is provided and includes: (a) providing a super paramagnetic bead in contact with a droplet comprising a starting concentration and starting quantity of the substance and having a starting volume; (b) conducting one or more droplet operations to merge a wash droplet with the droplet provided in step (a) to yield a combined droplet; and (c) conducting one or more droplet operations to divide the combined droplet to yield a set of droplets. The set of droplets includes: (i) a droplet in contact with the super paramagnetic bead having a decreased concentration of the substance relative to the starting concentration; and (ii) a droplet which is separated from the super paramagnetic bead.10-22-2009
20110201026COMPOSITIONS AND METHODS FOR THE DETECTION OF ANTIBODIES TO NATIVE HUMAN LEUKOCYTE ANTIGEN - Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.08-18-2011
20090298094METHOD OF ANALYZING BIOCHEMICAL - A method of highly sensitive and quantitative luminescent analysis with the use of a detection device using a micro-channel and carrying a molecule which is capable of capturing a substance to be detected and bonded to a solid phase. A biochemical to be detected is captured in a channel-type device having a probe bonded to a solid phase. After labeling for luminescence, a luminescent reagent is flown thereto and the luminescence in the vicinity of the probe is optically detected.12-03-2009
20080305497Polymeric carriers for immunohistochemistry and in situ hybridization - Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.12-11-2008
20080248494Test Methods and Devices - A method and test device for differentiating between states of an analyte that can exist in different forms, such as follicle stimulating hormone (FSH). The method or test device uses two contemporaneous assays, the first of which does not differentiate between the two analyte states and the second of which does, and the assay results are compared. A novel pair of anti-FSH monoclonal antibodies that can be used together in a sandwich-format assay to differentiate pre-menopausal and post-menopausal FSH samples is disclosed.10-09-2008
20090162872COMPETITIVE RECEPTOR BINDING ASSAY FOR DETECTING BETA-GLUCANS HAVING IMMUNOMODULATORY ACTIVITY IN A HUMAN CELL - The present invention provides a method for detecting a beta-glucan having immunomodulatory activity in a human cell, which uses a test cell line that stably expresses human dectin-1 molecule on the cell surface and does not express other glucan receptors and a specific amount of a marker beta-glucan that specifically binds to human dectin-1 molecule for detection.06-25-2009
20090325194USE OF SPLA2 ACTIVITY FOR THE DIAGNOSIS OF A CARDIOVASCULAR EVENT - A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, includes:—determining the sPLA2 activity of the patient as a first risk marker—determining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL level—determining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, the odds ratio compared to the predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and/or vascular event. A new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2 is also disclosed.12-31-2009
20090325195POLYCLONAL-MONOCLONAL ELISA ASSAY FOR DETECTING N-TERMINUS PRO-BNP - A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma. In order to obtain antibodies with specific binding properties for targeted amino acid sequences within human proBNP, recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen. Polyclonal antibodies (PAb) to specific amino acid sequences were subsequently purified from goat serum by sequential affinity purification. Monoclonal antibodies were raised against specific polypeptides. Recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified in order to obtain material for use in calibration of a quantitative method for measurement of human NT-proBNP.12-31-2009
20130217036NEW DIAGNOSTIC TOOLS FOR CHARCOT-MARIE-TOOTH DISEASE - The present invention relates in particular to methods of detecting predisposition to or diagnosis and/or prognosis of Charcot-Marie-Tooth (CMT) and related disorders. More specifically, the invention relates to development, validation and application of new biomarkers, which can be used for detecting the presence or risk of CMT disease and related disorders. In particular, the present invention relates to metabolite, lipid, carbohydrate and proteinaceous biomarkers that can be measured in biological body fluids and easily available extracts of biopsies, which can be used to aid in the detection, prediction of drug treatment and follow up of this treatment of neurodegenerative disorders, including CMT disease. The present invention also relates to methods for identification of CMT disease subtypes, assessing the responsiveness to the treatments and the efficacy of treatments in subjects having CMT or a related disorder.08-22-2013
20100003702Procedure And Device For Determining The Concentrations Of At Least Two Ligands - In a procedure for determining the concentrations of ligands contained in a sample wherein a first ligand is bond-specific to a first receptor and a second ligand is bond-specific to a second receptor, the first receptor is immobilized on a first test site and the second receptor is immobilized on a second test site on a substrate. A competitor that is bond-specific to the second receptor is mixed with the sample so that it is present in a predetermined concentration in the mixture. The mixture is brought into contact with the substrate so that the first ligand and the second ligand and/or the competitor bind to the first receptor and the second receptor, respectively. Afterwards, the unbound components of the mixture are removed from the substrate. A first metering signal relative to the concentration of the first ligand bound to the first receptor and a second metering signal relative to the concentration of the competitor bound to the second receptor are then generated. The concentrations of the ligands in the sample are determined with reference to the metering signals and the known concentration of the competitor in the mixture.01-07-2010
20090011434Methods And Compositions For Diagnosing Breast Cancer - Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.01-08-2009
20080286812ALCOHOL OXIDASE-BASED ENZYME-LINKED IMMUNOSORBENT ASSAY - Disclosed is an assay for detecting an analyte. The method includes the steps of contacting a solution suspected of containing the analyte with capture antibodies specific for the analyte, wherein analyte contained in the solution is captured by the capture antibodies. Then contacting the capture antibodies with a solution containing the analyte attached to an alcohol oxidase (AOX) enzyme, to yield captured, labeled analyte. Then contacting the capture antibodies with a reagent mixture that generates a first signal proportional to the captured, labeled analyte and quantifying the first signal. And then measuring concentration of the analyte in the unknown sample by comparing the first signal to standard curve of signals. The assay can be implemented in an ELISA format.11-20-2008
20080286811Cyr61 as a Biomarker for Diagnosis and Prognosis of Cancers of Epithelial Origin - Urinary Cyr61 protein levels are up regulated in patients that have cancers of epithelial origin, i.e. breast cancer and ovarian cancer. Accordingly, the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. Further, the amount of Cyr61 protein detected in a urine sample correlates with disease status such that Cyr61 levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of Cyr61 in urine provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient.11-20-2008
20110229912ANTI-PREPROPROTEIN AND ANTI-PREPROTEIN ANTIBODIES AS IMMUNOHISTOCHEMICAL MARKERS - It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.09-22-2011
20090220993Method and Compositions for Specifically Detecting Physiologically Acceptable Polymer Molecules - The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.09-03-2009
20120142025Ratiometric Immunoassay Method and Blood Testing Device - The invention is to devices and methods for rapid determination of analytes in liquid samples. The devices and methods incorporate a sample dilution feature and multiple immunosensors for performing a ratiometric immunoassay on a first analyte and a second analyte, for example, hemoglobin and hemoglobin A1c or albumin and glycosylated albumin. The devices are preferably capable of being used in the point-of-care diagnostic field.06-07-2012
20120171698METHOD AND DEVICE FOR RAPID PARALLEL MICROFLUIDIC MOLECULAR AFFINITY ASSAYS - Disclosed are methods and devices for rapid parallel molecular affinity assays performed in a microfluidic environment. The invention exploits hydrodynamic addressing to provide simultaneous performance of multiple assays in parallel using a minimal sample volume flowing through a single channel.07-05-2012
20090220994METHODS FOR DIAGNOSIS OF CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME - The present invention relates to methods for diagnosis of chronic prostatitis/chronic pain pelvic syndrome (CP/CPPS). We have found specific biomarkers that are present in higher concentrations in patients that have chronic prostatitis/chronic pain pelvic syndrome (CP/CPPS) as compared to subjects that have no symptoms of CP/CPPS. In particular, uromodulin (THP), aminopeptidase N (AMPN), dipeptidylpeptidase IV (CD26), neprilysin (NEP), zinc-α-2-glycoprotein (ZA2G) and alkaline phosphatase (ALP) were found to be present at higher concentrations in CP/CPPS patient urine that is voided after prostatic message. Accordingly, the invention is directed to methods for diagnosis of CP/CPPS by monitoring the levels of at least one of these proteins in post-prostatic massage urine, as well as to diagnostic kits designed for diagnosis of CP/CPPS.09-03-2009
20090239245METHOD FOR DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS - The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy.09-24-2009
20120196300Neurodegenerative Markers for Psychiatric Conditions - The present invention relates to methods for detecting a psychiatric condition optionally associated with a depression comprising the steps of measuring the concentration of at least one in vivo degradation product of tryptophan. Further, the present invention relates to the use of said values as predictive markers for the detection of a psychiatric condition optionally associated with a depression and a kit containing means for detecting said values.08-02-2012
20130122519Method for Detection of Ischemic Strokes - The present invention relates to the identification and use of diagnostic markers for ischemic stroke of the lacunar subtype. The invention relates to devices and kits for performing these methods.05-16-2013
20090053740AGGLUTINATION-BASED METHOD FOR FAST DETECTION, ISOLATION AND QUANTIFICATION OF APOPTOTIC CELLS - The present invention relates to methods and kits for the detection, isolation and quantification of apoptotic cells based on the apoptotic cells' increased expression of alpha-D-mannose and/or beta-D-galactose containing glycoproteins. Lectins that bind to alpha-D-mannose and beta-D-galactose-rich glycoconjugates are used in the methods and kits for agglutination tests for the detection, isolation and quantification of apoptotic cells. Lectins may be used to stimulate the agglutination of cells and apoptosis may be detected by assessing the concentration of lectins required to agglutinate a cell population and comparing the concentration to predetermined values for intact cells and cells in various stages after induction of apoptosis.02-26-2009
20100184091Method for determining MIF content - The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF.07-22-2010
20100190189METHODS FOR DETECTING BIOMOLECULES IN A SAMPLE - The invention develops a high-throughput screening method based on charcoal-sorbent peptide binding assay (CPBA) which does not need a solid phase and can simultaneously detect plural target biomolecules in a sample. The method of the invention can achieve high-throughput screening of biomolecules (such as antibodies and antigens) with a molecular weight of more than 10 KD.07-29-2010
20120270235MEMBRANE BIOSENSOR HAVING MULTI-HOLE FILM ATTACHED THERETO AND METHOD FOR MEASURING IMMUNOLOGICAL REACTION OR ENZYMATIC REACTION USING THE SAME - The present invention relates to a membrane sensor having a multi-hole film attached thereto and a method for measuring immunological reactions or enzymatic reactions using the same. More specifically, the present invention relates to a membrane sensor in which a multi-hole film is joined to the top of a membrane on which receptors are immobilized, and a method for measuring immunological reactions or enzymatic reactions using the same. The present invention makes it possible to adjust the sensitivity of membrane biosensors by adjusting the hole size in the multi-hole film and so makes it possible to measure analytes with a high degree of sensitivity using just a small amount of sample, and makes it possible to simultaneously measure diverse types of analyte by attaching various types of receptor on the membrane sensor.10-25-2012
20100216162Immunological Method, Test Kit and Device for the Determination of the Analyte Content of a Sample - The present invention relates to immunological methods for the determination of the analyte content in samples as well as to test kits and devices for performing the methods of the invention. In particular, the present invention relates to the analysis of samples of breeding animals, such as raw milk and serum, for an assessment of desired characteristics of the animal(s) tested, such as pregnancy, optimum point of insemination or diseases, wherein said analysis is easy to handle, time efficient and can be carried out on-site.08-26-2010
20110059466SUPPORT FOR ELECTROPHORESIS INCLUDING HYDROPHOBIC POLYMER MEMBRANE, AND ELECTROPHORETIC SEPARATION METHOD USING THE SAME - There is provided a membrane electrophoresis which renders possible glycan analysis of polysaccharide and glycoprotein by separating protein, glycoprotein or polysaccharide by electrophoresis, followed by carrying out a glycan-releasing treatment of the membrane used in the electrophoresis, or a membrane electrophoresis which renders possible detection of the same by an immunostaining which uses an antibody, wherein a layer containing a hydrophilic polymer is formed on a hydrophobic polymer membrane by coating the hydrophilic polymer on the whole surface of the hydrophobic polymer membrane or by soaking the hydrophobic polymer membrane in a solution of the hydrophilic polymer, which is used as a substrate for electrophoresis.03-10-2011
20100216163LECTIN-BASED GLYCAN ASSAY - The invention relates to the use of deglycosylated detectors, especially secondary antibodies, for the determination of sugar structures of proteins, especially recombinant proteins. It further relates to the use of deglycosylated enzymes in the determination of sugar structures with the aid of an enzyme-substrate reaction; the invention further relates to a method of determining the sugar structures of proteins, a sugar determination kit and the use of said kit for the determination of sugar structures, especially of recombinant therapeutic proteins, preferably immunoglobulins.08-26-2010
20120244555METHOD OF DIAGNOSING MILD TRAUMATIC BRAIN INJURY - The present invention relates to a method of determining whether a subject has suffered a mild traumatic brain injury. The method comprises selecting a subject exposed to a head trauma; and determining whether a body fluid sample obtained from the selected subject comprises smaller than normal high density lipoprotein (HDL) particles, larger than normal HDL particles, or both; wherein detection of the smaller than normal HDL particles, larger than normal HDL particles, or both, indicates that the subject has suffered a mild traumatic brain injury.09-27-2012
20100240070Nonseparation Assay Methods Using Peroxide Generating Enzymes - Nonseparation assay methods using peroxide generating enzymes in combination with a solid support for analyte detection are disclosed. The present assay methods provide a high degree of sensitivity, are simple and efficient to perform, and are excellent tools for diagnostic and high through-put screening applications.09-23-2010
20090075300METHODS AND COMPOSITIONS FOR THE DETECTION OF CERVICAL DISEASE - Methods and compositions for identifying high-grade cervical disease in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in high-grade cervical disease. In particular claims, the body sample is a cervical smear or monolayer of cervical cells. The biomarkers of the invention include genes and proteins that are involved in cell cycle regulation, signal transduction, and DNA replication and transcription. In particular claims, the biomarker is an S-phase gene. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.03-19-2009
20120142024MEANS AND METHODS FOR THE DETERMINATION OF THE AMOUNT OF NEUROTOXIN POLYPEPTIDE AND OF ITS CATALYTIC AND PROTEOLYTIC ACTIVITIES - The present invention pertains to the field of tools for ensuring manufacture of polypeptides and quality control. Specifically, it relates to a method for determining the amount of processed (active) neurotoxin polypeptides in a solution comprising processed neurotoxin polypeptides and partially processed or unprocessed neurotoxin polypeptides. The present invention further relates to a device for determining the amount of neurotoxin polypeptides and a kit adapted to carry out the method of the present invention.06-07-2012
20120142026Assay Devices with Integrated Sample Dilution and Dilution Verification and Methods of Using Same - The invention is to devices and method for rapid determination of analytes in liquid samples by various assays including immunoassays incorporating a sample dilution feature for forming a diluted sample for analysis. The devices and methods also include a dilution verification feature for verifying the degree of dilution of the diluted sample. The devices preferably are capable of being used in the point-of-care diagnostic field is provided.06-07-2012
20110151482AUTOMATED DEVELOPER FOR IMMUNO-STAINED BIOLOGICAL SAMPLES - Disclosed herein are systems and methods for the developing of immuno-stained biological samples. The systems disclosed herein are automated and are configured to control one or more steps of the developing procedure. Reagents may be added using automatic syringe dispensing. Reagent temperature, reagent stirring, and wash procedures are programmable and can be separately controlled for separate immuno-staining procedures that are performed at the same time.06-23-2011
20110244483ASSESSMENT OF PROTEIN DEGRADATION BY MEASUREMENT OF COLLAGEN FRAGMENTS - A method of assay measuring in a biological sample fragments of a protein that contain an N-terminal neo-epitope and a C-terminal neo-epitope, each generated by protease cleavage of said protein, comprises binding the N-terminal neo-epitope with a first specific antibody and binding the C-terminal neo-epitope with a second specific antibody, and detecting the extent of dual binding of said antibodies.10-06-2011
20110244482ASSESSMENT OF SUBCHONDRAL BONE REMODELLING BY MEASURING CATHEPSIN K FRAGMENTS OF COLLAGEN TYPE II - A method of assay to determine the extent of collagen type II resorption activity comprising measuring the level of fragments of collagen type II that contain a cathepsin K generated neo-epitope not shared by collagen type I by binding the neo-epitope with an antibody specific for the neo-epitope and detecting the level of binding of said binding partner.10-06-2011
20100136581DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS - The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide and methods of treating malignant neoplasms by inhibiting HAAH.06-03-2010
20100021944Method for Decreasing Interference in Results of Immunochemical Methods - Methods and materials are provided for decreasing or eliminating interference from molecules resulting from upstream immunochemical procedures, such as Immunoprecipitation, that employ an Immunoglobulin Binding Molecule (an IBM, e.g., Protein A) in subsequent downstream methods, such as Western Blot. An effective amount of a ligand of the IBM is used to block the IBM or fragments of the IBM on a support membrane used in the downstream method. In another embodiment, a secondary antibody that is specific either for heavy chain or light chain antibody fragments or that recognizes intact antibody molecules but does not recognize individual antibody fragments may be employed with the ligand of the IBM.01-28-2010
20100055717SAMPLING AND ASSAY DEVICE TOGETHER WITH METHODS FOR USE THEREOF - An immunochemical sampling device, kits including the sampling device, processes for production of the sampling device, and methods for use of the sampling device in lateral flow immunoassays. The sampling device comprises a solid support that is partially wrapped in a porous carrier, then covered in a hydrophobic cover. At its distal end, the porous carrier comprises a labeled binding reagent that is retained in the solid support until released into controlled flow with the liquid sample when the sampling device is brought into contact with a test strip.03-04-2010
20100055716DETECTION INSTRUMENT, ANALYSIS DEVICE, AND DETECTION METHOD - A detection instrument of the present invention includes: a flow path through which a sample to be examined flows, the flow path having a plurality of detection areas in each of which a target substance in the sample is detected, the plurality of detection areas respectively including detection sections and immobilizing sections each of which immobilizes an antibody, and the plurality of detection areas being separated by bulbs. As such, it is possible to provide a detection instrument which can detect plural kinds of target substances in a single flow path.03-04-2010
20090215082Doxorubicin Immunoassay - Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.08-27-2009
20110097740REAL-TIME CONTINUOUS DETECTION DEVICE - Provided is a real-time continuous detection device for detecting an analyte in a sample including: a sample inflow channel; a sample assay site; and a sample outflow channel, wherein the sample assay site includes a reversible capturing recognizing component and a sensor which detects a signal generated from a binding body of the analyte and the reversible capturing recognizing component. According to the real-time continuous detection device, it is possible to measure a change in concentration of the analyte in real time by continuously recycling the reversible capturing recognizing component. The real-time continuous detection device can be used to detect or assay living organism metabolites, a protein, a hormone, a nucleic acid, a cell, a food test material, an environment contaminant, national-defense chemical, biological and radiological test materials, or the like. Accordingly, the real-time continuous detection device can be applied to medical, public health, national defense, environment, food, veterinary, and biotechnology industries.04-28-2011
20110086365Method for Sensing a Chemical - The present invention relates to a method for detecting an analyte (04-14-2011
20110076694METHOD OF ASSESSING MAMMALIAN EMBRYO QUALITY - A method of assessing the health of each oocyte or embryo of a mammal from a plurality of oocytes/embryos of the mammal is provided. The method comprises the steps of: measuring gap junctional coupling strength or connexin43 expression of follicular cells associated with each oocyte; and identifying the gap junctional coupling strength/connexin43 expression of follicular cells associated with each oocyte, wherein the greater the coupling strength/connexin43 expression of follicular cells associated with an oocyte relative to the coupling strength/connexin43 expression of follicular cells associated with each other oocyte, the healthier the oocyte and the embryo resulting from that oocyte. Kits for conducting these methods are also provided.03-31-2011
20110076695IMMUNOASSAY ANALYZER AND IMMUNOASSAY METHOD - The present invention provides an immunoassay analyzer capable of discriminating between normal coloring due to a specific immunoreaction and abnormal coloring due to a cause other than the specific immunoreaction in a measurement region of a sample analysis tool. An immunoassay analyzer 03-31-2011
20120149033Antigen Binding Molecules that Bind EGFR, Vectors Encoding Same, and Uses Thereof - The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.06-14-2012
20120149034BIOMARKER FOR MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS, AND METHOD USING SAID BIOMARKER TO DETECT MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS - Methods are provided that detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence. Novel biomarkers are also provided for cognitive impairment and non-psychiatric disease, as well as methods for detecting cognitive impairment using such biomarkers. Specifically, a biomarker for diagnosis is provided that comprises a protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of an amino acid sequence expressed by SEQ ID NO: 1, 3, 6, 8, 10, 13, 15, 18, or 20 and selected from the group of partial peptide in these proteins consisting of an amino acid sequence expressed by SEQ ID NO: 2, 4, 5, 7, 9, 11, 12, 14, 16, 17, 19, or 21.06-14-2012
20100297669NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 191P4D12(b) USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 191P4D12(b) and its encoded protein, and variants thereof, are described wherein 191P4D12(b) exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 191P4D12(b) provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 191P4D12(b) gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P4D12(b) can be used in active or passive immunization.11-25-2010
20100297670METHODS FOR DETECTION OF IMMUNOSUPPRESSANT DRUGS - Methods and reagents are disclosed for enhancing the bioavailability of a hydrophobic drug, and in some embodiments for determining a hydrophobic drug, in a sample suspected of containing a hydrophobic drug. A combination is formed in a medium where the combination comprises the sample, a hemolytic agent where a determination of the hydrophobic drug is conducted, and a bioavailability agent for the hydrophobic drug. The bioavailability agent comprises an ionic detergent comprising a chain of at least 10 carbon atoms or a non-ionic detergent comprising a chain of at least 15 repeating ethylene oxide units or propylene oxide units or a combination of ethylene oxide units and propylene oxide units. The concentration of the bioavailability agent in the medium is sufficient to enhance the bioavailability of the hydrophobic drug. The medium is incubated under conditions for enhancing the bioavailability of the hydrophobic drug, and in a determination of the hydrophobic drug under conditions for hemolyzing cells in the sample. For determination of the hydrophobic drug, reagents for determining the presence and/or amount of the hydrophobic drug in the sample are added to the medium. The reagents comprise at least one antibody for the hydrophobic drug. The medium is examined for the presence of a complex comprising the hydrophobic drug and the antibody for the hydrophobic drug. The presence and/or amount of the complex indicates the presence and/or amount of the hydrophobic drug in the sample.11-25-2010
20110256554METHODS FOR PREDICTING PREGNANCY OUTCOME IN A SUBJECT BY HCG ASSAY - The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.10-20-2011
20110053181METHOD FOR DETECTING OBJECTIVE SUBSTANCE AND KIT FOR DETECTING OBJECTIVE SUBSTANCE - A method for detecting an objective substance in a sample using a chromatographic test device having a detection region on which a capture substance capable of binding to the objective substance is immobilized, comprising: mixing the sample and an enzyme-labeled substance capable of binding to the objective substance; trapping the objective substance binding to the enzyme-labeled substance by the capture substance in the detection region, by adding the liquid mixture to the chromatographic test device; adding an anionic surfactant-containing reagent to the detection region in which the objective substance is captured; reacting a luminescent substrate with the enzyme of the enzyme-labeled substance binding to the capture substance through the objective substance in the detection region; and detecting the objective substance in the sample by detecting luminescence generated from the detection region by the reaction of the luminescent substrate with the enzyme. A kit is also disclosed.03-03-2011
20110027803Compositions and Methods for Maintenance of Fluid Conducting and Containment Systems - Latently detectable small molecules, or ‘labels’, used for monitoring of treatment substances in fluid conducting and containment systems. A composition comprising the treatment substance and the label, a method of manufacturing the composition, a method and kit for use in monitoring the treatment substances in a fluid conducting and containment system, and a method for treating such a system using the composition are also disclosed.02-03-2011
20110136142IMMUNOCHROMATOGRAPHY METHOD - It is an object of the present invention to provide an immunochromatography method capable of measuring a sample in a low concentration range and a high concentration range by setting the measurable range of the sample much wider than the conventional measurable range. The present invention provides an immunochromatography method, which comprises: spreading a test substance, a first labeling substance modified with a first binding substance that binds to the test substance, and a second labeling substance modified with the first binding substance that binds to the test substance, which are in a mixed state, on an insoluble carrier; and capturing the test substance, the first labeling substance, and/or the second labeling substance at a reaction site on the insoluble carrier having a substance having ability to bind to the first binding substance that binds to the test substance, so as to detect the test substance, wherein the first labeling substance is a labeling substance that causes an amplification reaction, and the second labeling substance is a labeling substance that does not substantially influence on the amplification reaction.06-09-2011
20110136141PEPTIDE REAGENTS AND METHOD FOR INHIBITING AUTOANTIBODY ANTIGEN BINDING - The present disclosure provides immunoassays and kits for detection or quantification of an protein of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte.06-09-2011
20120064544Methods of Diagnosing Hypophosphatemic Disorders - The present invention relates to methods of diagnosing hypophosphatemic disorders.03-15-2012
20100120067H. Meleagridis Assay - Methods for the detection or quantification of antibodies against 05-13-2010
20090197283DEVICES AND METHODS FOR THE COLLECTION AND DETECTION OF SUBSTANCES - The present invention is a single self-contained device for collecting, transferring, extracting, and testing for the presence of a target analyte in a sample obtained from a surface by swabbing, solid materials (pills, capsules, unknown powders), air samples and biological and non-biological fluids. The device includes a swab, a retention well including eluent fluid, and analysis technologies which can include but are not limited to lateral flow testing analysis. The major improvement is the invention of rinsing the swab with proprietary elution fluid prior to testing thereby not compromising the chemistry and allowing for a wide variety of applications under extremely hot or cold field conditions. Also, the device is in one self-contained unit instead of having a separate water dropper or spray. Moreover, the shape of the device is similar to a magic marker so it is more substantial than any drug tester on the market, as well in certain embodiments it can have grips resembling a gun and in certain embodiments can even emit sounds or smells when a surface is wiped or a positive test is attained08-06-2009
20090176253Antibody conjugates - Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.07-09-2009
20090176251Methods for Diagnosing Celiac Disease Based on the Level of Anti-Gliadin and Anti-tTG IgA and IgG Antibodies - The present invention is in the field of diagnosing celiac disease. More particularly, the present invention relates to a method to diagnose celiac disease based on the level of anti-gliadin and anti-tissue transglutaminase antibodies.07-09-2009
20110189701CENTRIFUGAL MICRO-FLUIDIC DEVICE AND METHOD FOR DETECTING ANALYTES FROM LIQUID SPECIMEN - A centrifugal micro-fluidic device detecting analytes in a liquid specimen and a method of detection of analytes from a liquid specimen using the micro-fluidic device are provided. Reaction efficiency is increased using a repetitive flow of the liquid specimen induced by an alternating combination of capillary force and centrifugal force, thereby enhancing detection sensitivity.08-04-2011
20110189700CYR61 AS A BIOMARKER FOR DIAGNOSIS AND PROGNOSIS OF CANCERS OF EPITHELIAL ORIGIN - Urinary Cyr61 protein levels are up regulated in patients that have cancers of epithelial origin, i.e. breast cancer and ovarian cancer. Accordingly, the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. Further, the amount of Cyr61 protein detected in a urine sample correlates with disease status such that Cyr61 levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of Cyr61 in urine provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient.08-04-2011
20110189699AUTOANTIBODIES FOR PROTEIN ANTIGENS AS MARKERS FOR CANCER OF GINGIVO-BUCCAL COMPLEX - The present invention relates to identification of a set of proteins, which elicit an autoantibody response in patients with cancer of gingivo-buccal complex. Systematic comparisons of serum samples from clinically normal individuals and from patients with cancer of gingivo-buccal complex has revealed significant differences in the presence of autoantibodies in sera against cellular antigens present in a cancer cell line. The autoantibody response to a single or combination of these protein antigens serves as a novel marker and can be utilized for screening, early detection, prognosis, and potential target for therapy. The invention also provides for the use of the identified protein antigens in immunoassays designed to detect the presence of serum antibodies to the specific protein antigens in sera from individuals that harbor such antibodies. The invention also relates to the use of the identified antigens as immunogens for stimulation of an immune response in patients expressing such protein antigens. The invention is demonstrated by way of example in which elevated levels of circulating antibodies reactive against tumor specific antigens were identified in sera derived from patients with cancer of gingivo-buccal complex. The utility of identified antigens for early detection is assessed by analysis of sera from patients with leukoplakia of gingivo-buccal complex.08-04-2011
20120309024Electrophoretically Enhanced Detection of Analytes on a Solid Support - The present embodiments provide systems, kits and methods suitable for performing dry or substantially dry electro-blotting analyses on immobilized protein or nucleic acid samples. Electro-blotting performed according to the presently described embodiments may include a step whereby detection of one or more immobilized proteins or nucleic acids is electrophoretically accelerated. Methods for performing electro-blotting of immobilized proteins or nucleic acids may include applying an electric voltage to one or more reagents typically used in protein or nucleic acid blotting procedure. The one or more reagents may be absorbed on a suitable carrier matrix. Electro-blotting performed in accordance with the systems and methods described herein may be performed under substantially dry conditions (i.e., with little or no aqueous buffers).12-06-2012
20100021943Methods for differentially detecting a multimeric form from a monomeric form of a multimer-forming polypeptide through three-dimensional interactions - The present invention relates to a method for differentially detecting a multimeric form from a monomeric form of a multimer-forming polypeptide in a biosample, which comprises the steps of: (a) preparing a carrier-capturing antibody conjugate by binding a capturing antibody to the surface of a solid phase carrier in a three dimensional manner, wherein the capturing antibody is capable of recognizing an epitope on the multimer-forming polypeptide; (b) preparing a detection antibody, wherein an epitope recognized by the detection antibody is present at a position in the multimer-forming polypeptide to cause a steric hindrance by the capturing antibody bound to its epitope to prevent the binding of the detection antibody to the multimer-forming polypeptide; (c) contacting simultaneously the carrier-capturing antibody conjugate and the detection antibody to the biosample; and (d) detecting the formation of a carrier-capturing antibody-multimeric form-detection antibody complex.01-28-2010
20090186368Assay with reduced background - In an assay, an analyte in a sample is contacted with a thermostable reporter adenylate kinase coupled to a binding agent specific for the analyte, wherein a complex is formed. ADP is added, and then formation of ATP is monitored. Prior to the addition of ADP, endogenous kinase and uncomplexed thermostable reporter adenylate kinase is substantially removed by washing and residual endogenous kinase is inactivated by heating. Prior to contacting the analyte with the thermostable reporter adenylate kinase, the sample has a background activity of at least 300,000 Relative Light Units per mg protein per ml sample when measured in the presence of luciferin/luciferase by a luminometer.07-23-2009
20090068682IMMUNOLOGICAL ASSAY FOR PLASMIN-DIGESTED PRODUCTS OF STABILIZED FIBRIN - A method of immunologically analyzing plasmin-digested products of stabilized fibrin, characterized by using a combination of a monoclonal antibody (a) which does not react with stabilized fibrin, fibrinogen, and plasmin-digested products of fibrinogen, but reacts with a neoantigen which is newly exposed in a D domain by digesting stabilized fibrin with plasmin, and a monoclonal antibody (b) which recognizes a site different from that recognized by the monoclonal antibody (a), and specifically reacts with plasmin-digested products of stabilized fibrin, wherein one of the monoclonal antibodies (a) and (b) is carried on a magnetic particle, and the other is labeled with an enzyme, and a chemiluminescent substrate is used as a substrate for the enzyme, is disclosed.03-12-2009
20110136143MODIFIED CARDIOLIPIN AND USES THEREFOR - Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, oxidized cardiolipins, which may be conjugated with a variety of attachment molecules, such as BSA, KLH, biotin, synthetic protein MAPS, IgY, streptavidin, or avidin, are described. Such oxidized cardiolipin, alone or complexed with one or more attachment molecules, are useful to detect anti-lipoidal antibodies in subjects, for example, when used in lateral flow devices. Lateral flow devices are described that permit the detection of anti-lipoidal antibodies and that permit the co-detection of nontreponemal and treponemal antibodies in biological samples.06-09-2011
20110306062Babesia microti genomic clones containing novel antigens useful in the diagnosis of babesios - Disclosed are the cloning and expression of novel antigens in 12-15-2011
20100015636Colloidal Metal Conjugates - Colloidal metal conjugates can be produced in high concentrations suitable for direct use, for example, in immunoassays. The colloidal metal conjugates can be used in devices for qualitative, semi-quantitative, or quantitative determination of the presence of compounds in samples, including biological samples.01-21-2010
20110111428Method for Sensing a Chemical - The present invention relates to a method for detecting an analyte (05-12-2011
20120301898ASSESSING NON-ALCOHOLIC FATTY LIVER DISEASE - The document provides methods and materials related to assessing NAFLD in a mammal. For example, methods and materials for determining whether or not a mammal has an NAFLD are provided. In addition, methods and materials for determining whether a mammal with an NAFLD has a severe or mild form of the NAFLD as well as methods and materials for determining whether a mammal with an NAFLD is likely to experience a severe or mild form of the NAFLD are provided.11-29-2012
20120301896TSH ANTIBODIES FOR POINT-OF-CARE IMMUNOASSAY FORMATS - The invention relates to antibody characteristics used to design a whole blood Point of Care Thyroid Stimulating Hormone (TSH) immunoassay using an ELISA sandwich assay lacking one or more wash steps between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).11-29-2012
20110318755Universal Testing Platform for Medical Diagnostics - The invention relates to analysis of samples (for example, blood, urine, saliva, or swab). Some embodiments include a diagnostic testing platform. The platform may permit the analysis of a plurality of different samples with no or only minor modifications made to the platform. This platform may also reduce the number of steps performed by a user, and offer increased sensitivity and precision. The platform may be integrated with a low-cost instrument and provide an accurate digital analysis of the reaction.12-29-2011
20110318754Reduction in False Results in Assay Measurements - Methods and reagents are disclosed for detecting a false result in an assay measurement for determining a concentration of an analyte in a sample suspected of containing the analyte. The method comprises measuring assay signal resulting from background only and measuring assay signal resulting from the presence of analyte in the sample plus background and subtracting the first measurement from the second measurement to determine the concentration of analyte in the sample. For example, a measurement result 1 is determined by means of an assay conducted on a portion of the sample where analyte in the sample is substantially sequestered and a measurement result 2 is determined by means of the assay conducted on an equal portion of the same sample where analyte in the sample is substantially non-sequestered. Measurement result 1 is subtracted from measurement result 2 to determine the concentration of analyte in the sample.12-29-2011
20120003669Immunohistochemical staining method and immunohistochemical staining apparatus - An immunohistochemical staining apparatus for carrying out immunohistochemical staining includes a sample chamber (01-05-2012
20120058489USE OF MEGALIN IN URINE AS MARKER FOR DETECTING RENAL DISORDER - This invention provides a simple means for detecting a renal disorder, a diagnostic marker for a renal disorder that enables prognostic prediction of a renal disorder (e.g., diabetic nephropathy and IgA nephropathy) and evaluation of the degree of nephropathy at the phase of stage-II diabetic nephropathy by measuring the megalin level in urine associated with a renal disorder used for the detection means, and use of such marker. The invention also provides the use of human megalin obtained from the urine sample of a subject as a marker for detecting a renal disorder.03-08-2012
20120058490METHOD FOR DETECTING AN ANTIGEN - Provided is a method for detecting an antigen without use of a labeled-antibody. A support having an antibody and a multi-copper oxidase CueO immobilized thereon is brought into contact with a first buffer solution containing the antigen, a current is measured by a potentiostat method using the support and a second buffer solution, and when the measured current is greater than or equal to 1.5×(blank value), it is determined that the antigen exists. The second buffer solution contains a substrate of the CueO and has an ionic strength falling within a range of not less than 0.3 mM and not more than 1.0 mM.03-08-2012
20120156694PROTEINS USED FOR THE DIAGNOSIS OF LYME BORRELIOSIS - Chimera proteins including: (i) at least one sequence of a VlsE protein of a 06-21-2012
20120156693METHODS OF SIGNAL GENERATION AND SIGNAL LOCALIZATION FOR IMPROVEMENT OF SIGNAL READABILITY IN SOLID PHASE BASED BIOASSAYS - A method for generating and localizing a signal in a solid phase substrate detection system comprises applying a solution of target material to a substrate; binding the target with a specific affinity molecule having an attached label, the label comprising multiple signal precursor molecules; applying a carrier to the substrate, and treating the label to convert the signal precursor molecules to signal generating molecules. The carrier comprises solvent for the label and thickener for localizing the signal. The carrier may include developer that converts signal precursor molecules to signal generating molecules. Developer is not necessary if the signal precursor molecules are converted to signal generating molecules by e.g. temperature change, pH change, sonication, light irradiation, microwave heating. A test device for detecting target in a fluid sample, and a kit of parts for determining the presence of target in a fluid sample are also disclosed.06-21-2012
20120231476METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cathepsin B, Renin, Dipeptidyl Peptidase IV, Neprilysin, Beta-2-microglobulin, Carbonic anhydrase IX, and C-X-C motif chemokine 2 as diagnostic and prognostic biomarkers in renal injuries.09-13-2012
20110104714NON-PROTEOLYTIC METHOD FOR THE DETERMINATION OF ANALYTES IN KERATINIZED STRUCTURES - Methods that permit the rapid release of one or more analytes from head or body hair or other keratinized structures of an individual (who may previously have ingested one or more of the analytes) are provided. The methods can include contacting the keratinized structure with a reducing agent but not with a proteolytic agent. The methods can further include identification and quantification of the one or more analytes by known analytical techniques such as immunoassays. The described methods do not damage the analyte and do not cause harmful effects on a subsequently-used analyte detection probe (e.g., an antibody).05-05-2011
20120135422ANTI-GPCR ANTIBODY AND THE METHOD OF PRODUCING THE SAME - Disclosed is a discussion of a method for producing anti-mammalian GPCR antibody and of the antibody itself. Anti-mammalian GPCR antibody is produced through immunization involving exposure of fish to full-length or truncated mammalian GPCR, and anti-mammalian GPCR antibody that can be obtained by this method is also discussed.05-31-2012
20120164663Methylated Arginine Metabolites as Risk Predictors of Cardiovascular Disease - Methods for using methylated arginine metabolites and the arginine methylation index as markers for cardiovascular disease are described: The methods typically include determining the levels of dimethylarginine and N-monomethylarginine in a biological sample, comparing the levels of dimethylarginine and N-monomethylarginine to obtain an arginine methylation index; comparing the arginine methylation index to one or more control values; and using this comparison to characterize the subject's risk of having or developing cardiovascular disease or various complications associated therewith.06-28-2012
20120164662TEST METHOD ON RENAL DISEASES - Provided is a test method for the assessment of the necessity of renal biopsy in a subject to be tested, who is suspected of having a renal disease. Specifically provided are a test method for a renal disease, including using urinary podocalyxin and one or more additional markers in combination, and a test reagent for use in the test method and a test reagent kit for use in the test method. The present invention allows the discrimination of a poor prognosis group even for poor prognosis cases with no overt findings in a conventional test method, and thus allows the assessment of a renal disease, the assessment of the necessity of renal biopsy, prognostic prediction, and the like to be performed exactly.06-28-2012
20100209944ADAMTS-7 AS A BIOMARKER FOR CANCERS OF EPITHELIAL ORIGIN - ADAMTS-7 expression and activity are up regulated in patients that have cancers of epithelial origin. Accordingly, the present invention is directed to methods diagnosis of cancers of epithelial origin (e.g. breast cancer, prostate cancer, bladder cancer, brain cancer and hepatic cancer). In particular, the presence of ADAMTS-7 in a biological sample is indicative of cancer of epithelial origin. Thus, measuring the level of ADAMTS-7 in biological samples (e.g. urine or blood) provides a quick, easy, and safe screen that can be used to diagnose cancer in a patient.08-19-2010
20100209945METHOD FOR PREPARING ANTIBODY MONOLAYERS WHICH HAVE CONTROLLED ORIENTATION USING PEPTIDE HYBRID - The present invention relates to a method for preparing an protein monolayer using a peptide hybrid for protein immobilization, more precisely a peptide hybrid for protein immobilization which has improved solubility by introducing a PEG linker and a proper reaction group to the oligopeptide having specific affinity to selected types of proteins and is designed to provide enough space between solid substrates and proteins immobilized, whereby various solid substrates treated by the hybrid catch specific proteins effectively on. The peptide hybrid for protein immobilization of the present invention facilitates the control of orientation of an antibody on various solid surfaces and immobilization of various antibodies of different origins or having different isotypes with different affinity. Therefore, the surface treatment technique using the peptide hybrid of the invention can be effectively used for the production of various immunosensors and immune chips.08-19-2010
20100173331NOVEL NOTCH-ORIGIN POLYPEPTIDES AND BIOMARKERS AND REAGENTS USING THE SAME - It is intended to provide extracellular markers whereby Notch signal transduction can be detected. Polypeptides (Nβ), which are novel peptides originating in Notch protein and released form cells in the step of the nuclear migration of NICH (Notch intracellular cytoplasmic domain) due to the extracellular digestion and the subsequent protein digestion in the membrane during a series of the Notch protein digestion, are referred to as markers. These peptides (Nβ) are released from the cells in proportion to the Notch signal depending on presenilin. By detecting these peptides, the Notch signal transduction, cell differentiation, cell tumorigenesis, apoptosis, Alzheimer's disease, etc. can be monitored.07-08-2010
20100173330IMMUNOASSAY ASSEMBLY AND METHODS OF USE - The present invention relates to an improved system for efficiently and accurately performing immunoassays, such as ELISAs. The invention provides an immunoassay assembly which includes a flow-through unit and an aspiration pump. The immunoassay flow-through unit includes an outer seal; at least one bed support; an inner seal; and a packed non-porous bed. The unit is releasably attached to an aspiration pump which enables the controlled flow rate of liquid passing through the packed bed of the flow-through unit. The invention also provides a method of using the immunoassay assembly to identify analytical targets of interest.07-08-2010
20120077210Measuring G Protein Coupled Receptor Activation - The present invention relates to methods and polypeptides for detecting a compound in a sample. In particular, the present invention relates to the use of a cell-free composition comprising at least one G protein coupled receptor embedded in a lipid Mayer which when expressed in a cell the N-terminus of the G protein coupled receptor, or subunits thereof, is outside the cell and the C-terminus is inside the cell, and which is capable of binding the compound. Optionally, the composition also comprises at least one accessory molecule that directly or indirectly binds an intracellular loop and/or the C-terminus of the G protein coupled receptor. The G protein coupled receptor, and/or accessory molecule when present, in combination comprise a bioluminescent protein and an acceptor molecule, which enables bioluminescent resonance energy transfer (BRET) to be used to detect the compound binding the receptor.03-29-2012
20100047825IMMUNOASSAY REAGENTS AND METHODS OF USE THEREOF - The present invention provide reagents and methods of using the reagents, for example, on automated staining devices, that facilitate detection of two or more antigens in a sample simply and efficiently.02-25-2010
20120219966METHOD AND KIT FOR MEASURING COMPONENT TO BE ASSAYED IN SPECIMEN (AS AMENDED) - Methods and kits for measuring a component to be measured in a specimen are provided, which enable accurate measurements that are not affected by reaction temperatures or such when measuring the component to be measured, such as antigens.08-30-2012
20120178102CHARACTERIZATION OF GRANULOCYTIC EHRLICHIA AND METHODS OF USE - The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S1, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S1, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with ehrlichiosis; therapeutic uses, specifically vaccines comprising S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins or polypeptides or nucleic acids; and methods of preventing or inhibiting ehrlichiosis in an animal.07-12-2012
20100009389Method of Making and Using Versatile Positive Controls and Antibody Detection Assays - The present invention is in the technical field of ligand-binding assays for detection of antigen-specific antibodies. Specifically a method for preparation of a versatile positive control, components of which can be mixed and matched in numerous combinations to render positive controls for antigen specific antibodies of a wide variety of Immunoglobulin classes (e.g., IgG, IgA, IgM, IgE etc.) in both human and animals is described. Also disclosed are assay methods and kits in which the positive control components are used for detection of antigen-specific antibodies in biological and non-biological matrices.01-14-2010
20120225438SYSTEMS AND METHODS FOR DETECTING ANIMAL PREGNANCY - Testing systems and methods are disclosed for detecting a pregnancy marker of an animal. A test kit may include a first standard with a first concentration of the marker, a second standard with a second concentration of the marker lower than the first concentration, and at least three test surfaces coated with a biomolecular recognition element selected to bind with the marker. The test may also include a reagent solution with a conjugated biomolecular recognition element that binds with the marker, and a visual indicator that produces a visually detectable change when reacting with the conjugated biomolecular recognition element bound to each test surface. A detectable change generated by the marker from the sample with an intensity greater than the first concentration yields a pregnant result, lower than the second concentration yields a not pregnant result, and between the first and second concentrations yields a retest result.09-06-2012
20090098578ASBESTOS DETECTION METHOD, ASBESTOS DETECTION AGENT, ASBESTOS DETECTION KIT, METHOD FOR SCREENING CANDIDATE FOR AGENT AIMING AT PREVENTING OR TREATING DISEASE FOR WHICH ASBESTOS IS CAUSATIVE OR WORSENING FACTOR - The present invention provides a prompt and easy asbestos detection method and a method for screening a candidate for an agent aiming at preventing or treating a disease for which asbestos is a causative or worsening factor. It is possible to quickly and easily detect asbestos in a sample by finding a protein capable of binding specifically to asbestos, allowing the protein or a fusion protein of the protein and a reporter protein to bind to asbestos in the sample, and then detecting the protein or the fusion protein having been bound to asbestos. A substance inhibiting the binding of actin to asbestos, which has been found out as a protein capable of binding specifically to asbestos, is a candidate for an agent aiming at preventing or treating a disease for which asbestos is a causative or worsening factor.04-16-2009
20090061460TEST APPARATUS, PRODUCTION METHOD THEREFOR AND TEST METHOD - Test apparatus for detecting an analyte (A) contained in a sample liquid, comprising a dry porous carrier (03-05-2009
20120258473METHOD OF COLLECTING SPECIMEN AND METHOD OF DIAGNOSING SUBJECT TO DETECT UPPER DIGESTIVE SYSTEM DISEASE - A method of collecting a specimen of the present invention is used in detecting upper digestive system disease. The method of collecting a specimen includes: a step of positioning sampling equipment in the duodenum of the subject into which duodenal juice is secreted, the sampling equipment being used to collect and store the duodenal juice; a step of collecting duodenal juice naturally secreted in the duodenum using the sampling equipment; and a step of stopping collection of the duodenal juice when collection quantity of the duodenal juice reaches a predetermined quantity which is 3.0 ml or less.10-11-2012
20120258472SYSTEMS AND METHODS OF FLUIDIC SAMPLE PROCESSING - The present invention provides fluidic devices and systems that allow detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.10-11-2012
20120190046DEK as a urine based biomarker for bladder cancer - The present invention is directed to a method of detecting DEK protein in a urine sample. Methods and compositions are provided herein for detecting and diagnosing bladder cancer by chemical-induced precipitation of urine proteins, followed by filtration-induced concentration and Western blot analysis to specifically detect DEK protein. The present method permits specific detection of DEK protein in urine as a biomarker for bladder cancer in humans.07-26-2012
20120329073METHOD OF DETECTING PORK IN PROCESSED FOOD AND DETECTION KIT THEREFOR - [Object] To provide preparation of an ingredient derived from a specimen optimal for detecting by immunoassay pork in heated food with high performance and high sensitivity without causing non-specific reaction, a convenient and high-accuracy detection method using a polyclonal antibody obtained by using the ingredient, and a detection kit therefor.12-27-2012
20120329074MARKER FOR DETECTING GASTRIC CANCER AND METHOD FOR DETECTING GASTRIC CANCER - It is intended to provide a method for detecting gastric cancer, which is low invasive to a human test subject and has high detection sensitivity and accuracy. The present invention provides a method comprising measuring in vitro the amount of COTL1 protein, a variant thereof, and/or a fragment thereof in a body fluid sample derived from a human test subject, and detecting the presence or absence of gastric cancer affecting the test subject on the basis of the amount, and a kit for gastric cancer diagnosis comprising an antibody capable of specifically binding to the protein.12-27-2012
20090017469Use of Holographic Sensor - The present invention relates to a process for the detection of an analyte in a sample, comprising a) bringing the sample into contact with a first ligand which binds specifically to the analyte and which is immobilised on a substrate, and b) prior to or subsequent to step (a), bringing the sample into contact with a second ligand which binds specifically to the analyte and which includes a label: wherein the substrate comprises a holographic sensor comprising a support medium having a hologram disposed therein or thereon and the label causes an optical property of the sensor to change by interaction of the sensor with the label or, following the additional step of contacting the substrate with a reagent, by interaction of the sensor with a species produced by reaction of the label with the reagent, thereby indicating the presence of bound analyte.01-15-2009
20090017470Immunological analytical reagent for the determination of advance glycosylation end products (AGEs) - The invention provides a reagent for determination of Advance Glycosylation End Products (AGEs), comprising a suspension disposed with displaying carrier and the antigen or antibody immobilized on the surface of the said displaying carrier; and a test strip, comprising of: a base plate, and constitutive parts provided on said base plate, said constitutive parts consisting of a water absorption pad for the sample, a porous fiber membrane, a displaying carrier fiber block and at least one immobilized substance. After infusing the said reagent into the said test strip, the immunological reaction of the AGEs antigen or antibody can be determined based on the agglutination phenomenon or accompanied changes of absorbance or color and the presence or raised level of the AGEs in the diabetic patient can be known accordingly such that the practitioner can prevent the occurrence of the complicated condition, or block further the progression of the complications at the earlier stage.01-15-2009
20110124013Galactose-alpha-1,3-galactose-macromolecule conjugates and methods employing same - Methods and reagents are disclosed for conducting assays for IgE. Embodiments of the present reagents comprise a conjugate of a macromolecule and a compound comprising a galactose-α-1,3-galactose epitope. Embodiments of the present methods are directed to determining the presence and/or amount of an IgE specific for a galactose-α-1,3-galactose epitope in a sample. A combination is provided in a medium, which comprises the sample and a reagent for determining the presence and/or amount of an IgE specific for a galactose-α-1,3-galactose epitope in a sample wherein the reagent comprises a conjugate of a macromolecule and a compound comprising a galactose-α-1,3-galactose epitope. The combination is subjected to conditions for binding of the IgE to the reagent to form a complex. The presence and/or amount of the complex are detected and the amount of the complex is related to the presence and/or amount of IgE in the sample.05-26-2011
20110124012ASSAYS FOR HUMAN NT-PRO B-TYPE NATRIURETIC PEPTIDE, HUMAN PRO B-TYPE NATRIURETIC PEPTIDE AND HUMAN B-TYPE NATRIURETIC PEPTIDE - The present disclosure relates to assays for detecting and/or quantifying the amount of human NT-pro B-type natriuretic peptide, human pro B-type natriuretic peptide and human B-type natriuretic peptide in a test sample.05-26-2011
20130171662ASSAY - This disclosure relates to a diagnostic/prognostic assay for prostate cancer and including kits used in said assay.07-04-2013
20100330589NEEDLE ARRAY ASSEMBLY AND METHOD FOR DELIVERING THERAPEUTIC AGENTS - A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to deliver a substantially equal amount of fluid at any given location along its length. A driver is coupled to the actuators to selectively control the rate, volume, and direction of flow of fluid through the needles. The device can simultaneously deliver a plurality of fluid agents along respective axes in solid tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue, and based on the evaluation, candidate agents selected or deselected for clinical trials or therapy, and subjects selected or deselected for clinical trials or therapeutic treatment.12-30-2010
20110003314Hapten, Immunogens and Derivatives of Ascomycin Useful for Preparation of Antibodies and Immunoassays - The invention teaches derivatives of ascomycin and methods of preparing immunogens and other conjugates useful in immunoassays for quantitatively measuring concentrations of tacrolimus in patient specimens. Antibodies produced from the disclosed immunogens capable of binding to tacrolimus with cross-reactivity of no more than 5% with each of 15-O-demethyl tacrolimus, 31-O-demethyl tacrolimus, and 13,31-O-didemethyl tacrolimus, less than 40% with 13-O-demethyl tacrolimus, and less than 1% with cyclosporin, rapamycin, mycophenolic acid, prednisone, hydrocortisol, and prednisolone are described. Further, immunoassays for measuring the concentration of tacrolimus using such antibodies are taught.01-06-2011
20110003313AMPLIFIED LABELED CONJUGATE FOR USE IN IMMUNOASSAYS - A conjugate, for use as a detection reagent in an immunoassay, is based on a hydrophilic monodisperse macromolecule, i.e. a macromolecule having a substantially uniform size and shape, the macromolecule forming a practically useful and manageable carrier, to which carrier at least one binding entity and at least one label are bound.01-06-2011
20120129188CIRCULATING CYTOCHROME C AS BIOMARKER OF REPERFUSION INJURY AND RESPONSIVENESS TO MITOCHONDRIAL TARGETED INTERVENTIONS - The present invention relates generally to the use of circulating cytochrome c as a biomarker of reperfusion injury that results from whole body ischemia. Circulating levels of cytochrome c can be used as predictor of survival rates and to assess the effects of interventions aimed at ameliorating mitochondrial injury during reperfusion. Whole body ischemia may be the result of cardiac arrest or from other hemodynamic crises, such as hemorrhagic shock.05-24-2012
20120100558LUNG CANCER DIAGNOSIS - Diagnosis of lung cancer in a subject before onset of symptoms is described herein (i.e., in a pre-diagnostic subject), by screening a biological fluid from the subject for the presence therein of autoantibodies that are specific for one or more pre-diagnostic lung cancer indicator proteins, including LAMR1, and optionally additionally or alternatively including annexin I and/or 14-3-3-theta and/or other pre-diagnostic lung cancer indicator proteins as presently disclosed, as the defined antigens. Related methods, including for monitoring immune reactivity against lung cancer indicator proteins in a lung cancer patient, typing lung cancer subjects or characterizing lung tumors, and application of the described proteomics approach for the identification of additional pre-diagnostic lung cancer indicator proteins, are also contemplated.04-26-2012
20100261200Glycoprotein VI and Uses Thereof - The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.10-14-2010
20100167313ANTI-IDIOTYPE ANTIBODY AGAINST AN ANTIBODY AGAINST THE AMYLOID BETA PEPTIDE - The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid β peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid β peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid β peptide.07-01-2010
20130011860METHODS FOR DETECTING INSULIN AUTOANTIBODY - The present invention provides methods for detecting insulin autoantibody. Such methods can be used, for example, to predict susceptibility of and/or diagnose the presence of Type 1 diabetes in a subject. Some aspects of the invention also provide kits adapted for use in such methods. In particular, some aspects of the invention use proinsulin to detect the presence of insulin autoantibody.01-10-2013
20130011859Method and Apparatus for Performing Assays - An apparatus is provided for performing an chemical, biochemical, or biological assay on a sample comprising: a microfluidic assay cartridge (01-10-2013
20130011858METHODS FOR PREDICTING PREGNANCY OUTCOME IN A SUBJECT BY HCG ASSAY - The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.01-10-2013
20130017559Lateral Flow Assays With Time Delayed Components - A lateral flow device may include one or more enhancement elements, where the enhancement elements bind to the analyte sandwich to increase a detection signal in the test zone. In preferred embodiments, some or all of the enhancement elements are encapsulated.01-17-2013
20130171663METHOD AND KIT FOR MEASUREMENT OF ENDOTOXIN LEVEL USING BIOLUMINESCENT ASSAY - The present invention provides a method comprising allowing a reaction of a sample, a reagent containing Factor C, which can be activated by binding with endotoxin, and a synthetic luminescent substrate comprising a luminescent substrate bound to a peptide, for release of the luminescent substrate from the synthetic luminescent substrate, allowing a luminescent enzyme to act on the luminescent substrate released in the luminescent substrate release step, for measurement of the luminescence intensity, and quantifying the level of endotoxin in the sample based on a measured value obtained in the luminescence measuring step, the method enabling endotoxin to be simply and quickly measured at a level that cannot be detected in conventional methods for endotoxin measurement, without use of any dedicated measuring device.07-04-2013
20080220449Biomarkers and assays for Alzheimer's disease - Methods, compositions and systems are provided for diagnosing, stratifying, or monitoring the progression or regression of Alzheimer's disease (AD), the methods, compositions and systems comprise detecting in a sample a level of at least one AD biomarker, the AD biomarker comprising at least phosphorylated tau pT217, soluble tau oligomer, tau-amyloid-beta 1-42 complex, a fragment thereof or a combination thereof and comparing the level from the sample to a reference level of phosphorylated tau pT217, soluble tau oligomer, and/or tau-amyloid-beta 1-42 complex to diagnose or stratify or monitor the progression or regression of AD. In various embodiments, diagnostic assay and screening kits are provided. In various embodiments, the assay and kits provided can monitor the therapeutic effect of a drug and/or AD treatment. In various embodiments, the assay can be used to screen for drugs that disrupt the AD biomarker(s)09-11-2008
20080220448ANTIGENIC PROTEIN CONJUGATES AND PROCESS FOR PREPARING SAME - An improved process for the preparation of antigenic protein conjugates is provided. The conjugates preferably are formed through reaction with one or more free sulfhydryl groups in the antigenic protein. The process of the present invention preferably employs a trialkylphosphine as the reducing agent and allows for reduction of disulfide bonds in the antigenic protein and conjugation with a conjugate moiety, preferably in a single reaction vessel (i.e. “in situ”) because the process optimally does not require the removal of the reducing agent before subsequent addition of the sulfhydryl reactive agent. Antigenic protein conjugates prepared by the in situ process and their use in diagnostic immunoassays are also provided.09-11-2008
20120252036DIAGNOSTIC TESTS FOR ABNORMAL OVARIAN CONDITIONS - Methods and compositions, and a kit for diagnosing ovarian disorders including autoimmunity and ovarian cancer. Ovarian autoimmunity is associated with unexplained infertility or idiopathic premature ovarian failure that occurs in the absence of polyglandular disease. Methods and composition described herein are used to detect ovarian autoimmunity before the onset of ovarian dysfunction. Thus, those individuals are identified who would benefit from therapy to maintain, as well as restore, ovarian function.10-04-2012
20110269151CENTRIFUGAL MICRO-FLUIDIC DEVICE AND METHOD FOR IMMUNOASSAY - A centrifugal micro-fluidic device and an immunoassay method using the same are provided. The micro-fluidic device includes at least one micro-fluidic structure, the micro-fluidic structure including: a sample chamber receiving a fluid sample; a first reaction chamber which is connected with the sample chamber and contains at least one labeling conjugate; a second reaction chamber which is connected with the first reaction chamber and contains a capture binder; a buffer chamber which is connected with the second reaction chamber and contains an elution buffer; a detection chamber which is connected with the second reaction chamber and receives the at least one labeling conjugate; a plurality of channels through which the first reaction chamber, second reaction chamber, buffer chamber and detection chamber are interconnected; and at least one valve which is positioned in at least one of the plurality of channels, and opens and closes the channel11-03-2011
20130115622PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - Provided are a prophylactic and therapeutic agent for amyotrophic lateral sclerosis containing an HMG-CoA reductase inhibitor and a method of screening for a prophylactic and therapeutic drug for amyotrophic lateral sclerosis using an induced pluripotent stem cell derived from a patient with amyotrophic lateral sclerosis.05-09-2013
20130143234SAMPLE ANALYZING DEVICE AND SAMPLE ANALYZING METHOD - This invention provides a sample analyzing device and sample analyzing method designed to suppress nonuniform capture of magnetic particles (06-06-2013
20080206788Reagents and methods for the detection and quantification of vancomycin in biological fluids - Immunoassay reagents, methods and test kits for the specific quantification of vancomycin in a test sample are disclosed. The reagent comprises antibodies prepared with immunogens of FIG. 08-28-2008
20080199887COMPOUNDS AND METHODS FOR USE IN DETECTING GABAPENTIN - Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.08-21-2008
20110223617IMMUNOASSAYS FOR AUTOANTIBODIES IN CARDIOVASCULAR DISEASES - The present invention relates to the quantitative measurement of auto-reactive antibodies in a patient sample. In particular, the present invention is directed to, inter alia, a method for predicting the degree of cardiovascular injury in a patient following an ischemic event, said method comprising: immobilizing anti-NMHC II antibody on a solid support; adding a lysate of cardiac tissue to the solid support so that antigens in the lysate are captured by the immobilized antibody; adding a biological sample from the patient to said solid support, and incubating said sample for a time sufficient for IgM autoantibodies in the biological sample to bind to antigens in the cardiac tissue lysate; contacting said solid support with an anti-IgM antibody; removing unbound labeled antibodies; and determining the level of anti NMHC II autoantibodies in the biological sample by measuring the amount of labeled anti-IgM antibody bound to the solid support, wherein elevated levels of anti-NMHC II autoantibodies compared to normal individuals at time of patient admission indicates an increased risk of injury. Such methods are useful, inter alia, in the prognosis and monitoring of cardiovascular diseases.09-15-2011
20110275095Microarrays for Allergen-Specific IgE - Biological samples are assayed for the presence of IgE antibodies specific to unknown allergens in the samples. Known allergens conjugated to biotin are attached as an array of spots on a streptavidin-linked membrane. A sample is incubated with the membrane containing attached known allergens. After washing away excess sample, the membrane is contacted with a labeled anti-IgE, e.g. alkaline phosphatase-labeled anti-IgE, thus attaching anti-IgE to the IgE from the sample, now bound to known allergens. The excess labeled anti-IgE is washed away and the attached IgE remaining on the membrane identified by adding a substrate for the label, thus producing a measurable response.11-10-2011
20100317033METHODS AND MATERIALS FOR DETECTING FOOD CONTAINING ALLERGENS - This document provides methods and materials related to detecting allergens (e.g., food allergens) and/or specific antibodies in individualized consumers that are specific to an allergen (e.g., a food allergen). For example, methods and materials for assessing a food sample for the presence or absence of food allergens are provided. In addition, methods and materials for assessing if a particular human will react with those exact food allergens given his/her antibody profile are provided.12-16-2010
20100317032METHOD FOR DETECTING ANTIGEN AND ANTIGEN DETECTION DEVICE - Provided is a method for detecting an antigen in a sample, the method including: bringing an unlabeled polypeptide and a labeled polypeptide into contact with an antigen in a sample, the unlabeled polypeptide being one of a pair including a VH-region polypeptide and a VL-region polypeptide which are separate and capable of cooperatively recognizing the antigen, and the labeled polypeptide being the other of the pair including the separate VH-region polypeptide and the VL-region polypeptide and being labeled with an environmentally-responsive substance at a site where the environmentally-responsive substance does not inhibit binding of the antigen, and detecting a change in the environmentally-responsive substance caused by a change in the environment around the labeled polypeptide after the contact. Also provided is an antibody fragment polypeptide set including the unlabeled polypeptide and the labeled polypeptide.12-16-2010
20120282630MIXED-METAL SUBSTRATES FOR METAL-ENHANCED FLUORESCENCE - The present invention provides for mixed metal structures that can be deposited on a substrate or free in solution that exhibit several distinctive properties including a broad wavelength range for enhancing fluorescence signatures. Further, metal surface plasmons can couple and such diphase coupled luminescence signatures create extra plasmon absorption bands. The extra bands allow for a broad range of fluorophores to couple therefore making more generic substrates with wider reaching applications.11-08-2012
20120282629Enhancers of Protein Degradation - The present invention relates to compounds suitable for modulating huntingtin protein processing and useful for treating or preventing huntingtin-related disorders. The invention provides pharmaceutical compositions comprising said compounds and methods of syntheses thereof.11-08-2012
20110311990TETRANOR-PGEM/PGAM SPECIFIC IMMUNOGENS, ANTIBODIES, TRACERS, ASSAY KITS AND METHODS FOR MAKING SAME - Tetranor-PGEM/tetranor-PGAM-specific antibodies, immunogens used to generate them, the processes of their manufacture, and their uses for detecting and quantifying tetranor-PGEM in biological fluids for determining biosynthesis of PGE12-22-2011
20130189709Multiplanar Lateral Flow Assay with Sample Compressor - A sample compressor applies pressure to a sample collector and a sample application zone of a test strip to transfer a sample from the sample collector and a binding partner of an analyte to the sample application zone in a lateral flow device. At least one of the binding partners of the analyte is not located on the test strip prior to use of the lateral flow device. The test strip may be a universal test strip with no molecule that specifically binds the analyte is located on the test strip. The sample compressor may be a universal sample compressor also with no molecule that specifically binds the analyte on the sample compressor. The lateral flow device may also include one or more enhancement elements, where the enhancement elements bind to the analyte sandwich to increase a detection signal in the test zone.07-25-2013
20120021439SERIAL MULTIPLE ANTIGEN COLOCALIZATION IN PARAFFIN-EMBEDDED TISSUE - The present invention provides a novel method called Sequential IMmunoPeroxidase Labeling and Erasing (SIMPLE) that enables the simultaneous visualization of at least five markers within a single tissue section. Utilizing the alcohol-soluble peroxidase substrate 3-amino-9-ethylcarbazole (AEC), combined with a rapid non-destructive method for antibody-antigen dissociation, the present application discloses the ability to erase the results of a single immunohistochemical stain while preserving tissue antigenicity for repeated rounds of labeling. The present invention also provides methods for visualizing multiple antigens simultaneously.01-26-2012
20120021438Method of Detecting Target, Method of Suppressing Increase in Background and Detection Apparatus - Provided are a method of detecting a target with high accuracy, a method of suppressing an increase in background, and a detection apparatus.01-26-2012
20120021437TETRANOR-PGDM/PGJM SPECIFIC IMMUNOGENS, ANTIBODIES, TRACERS, ASSAY KITS AND METHODS FOR MAKING SAME - Tetranor-PGDM/tetranor-PGJM-specific antibodies, immunogens used to generate them, the processes of their manufacture, and their uses in assay kits for detecting and quantifying tetranor-PGDM and tetranor-PGJM in biological fluids for determining biosynthesis of PGD01-26-2012
20130196344SYSTEMS AND METHODS FOR COLLECTING TEAR FILM AND MEASURING TEAR FILM OSMOLARITY - A sample receiving chip comprising a substrate that receives an aliquot volume of a sample fluid and a sample region of the substrate, sized such that the volume of the sample fluid is sufficient to operatively cover a portion of the sample region. The energy imparted into the sample fluid is transduced by the sample region to produce an output signal that indicates energy properties of the sample fluid. The sample receiving chip also includes a channel formed in the substrate, the channel configured to collect the aliquot volume of a sample fluid and transfer the aliquot volume of sample fluid to the sample region.08-01-2013
20130196345METHODS FOR DETERMINING A WAVEFRONT POSITION ON A TEST STRIP - The present disclosure relates to methods for determining a wavefront position of a liquid on a surface of an assay test strip placing a liquid on the surface of the test strip; and acquiring one or more signals from the surface of the test strip at one or more times, comparing the one or more acquired signals to a threshold, wherein the wavefront position is a position on the surface of the test strip where a signal is greater than or less than a threshold (e.g., fixed or dynamic threshold). Such methods may be used to determine the wavefront velocity of a liquid on a surface of an assay test strip and the transit time of a liquid sample to traverse the one or more positions on the surface of the assay test strip.08-01-2013
20120045776MONOCLONAL ANTIBODY DS6, TUMOR-ASSOCIATED ANTIGEN CA6, AND METHODS OF USE THEREOF - The present application describes a monoclonal antibody selected from the group consisting of monoclonal antibody DS6, monoclonal antibodies that specifically bind to the antigen or epitope bound by monoclonal antibody DS6, and fragments of the foregoing that specifically bind to the antigen or epitope bound by monoclonal antibody DS6. Methods of use of such antibodies and the isolated antigen bound by such antibodies are also described.02-23-2012
20130203076COMPOSITIONS AND METHODS FOR DETECTION OF METHADONE METABOLITE - Methods and reagents are disclosed for conducting assays for EDDP. The reagents include a moiety selected from the group consisting of poly(amino acid) label moieties, non-poly(amino acid) label moieties, poly(amino acid) immunogenic carriers, non-poly(amino acid) immunogenic carriers, non-label poly(amino acid) moieties, and non-immunogenic carrier poly(amino acid) moieties linked to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine at the 3-position of one of the phenyl rings. Antibodies produced from immunogenic EDDP conjugates and labeled EDDP conjugates are employed in assays for determining the presence and/or amount of EDDP in samples suspected of containing EDDP.08-08-2013
20130203077QUANTITATION OF URINARY TISSUE FACTOR FOR THE DIAGNOSIS AND SCREENING OF CANCER - We provide a novel technological approach for quantitation of c-terminal fragment of uTF for the purpose of quantitation, diagnosis and population screening of cancer. We provide a rationale for measuring c-terminal fragment, methods for making assays, monoclonal and polyclonal antibodies, together with accepted methods of sample preparation. Taken together these proposals and ideas constitute a novel approach for diagnosis and population screening for cancers using urine from cancer patients. In addition we believe that our approach may be useful in the diagnosis of other pathological conditions.08-08-2013
20090035790HIGH SENSITIVITY IMMUNOASSAYS AND KITS FOR THE DETERMINATION OF PEPTIDES AND PROTEINS OF BIOLOGICAL INTEREST - The invention relates to immunoassays which allow the detection of polypeptides in samples with a higher sensitivity than assays of the state of the art. The invention also relates to kits which provide the components needed for carrying out said immunoassays.02-05-2009
20120301897ACETAMINOPHEN-PROTEIN ADDUCT ASSAY DEVICE AND METHOD - The present invention describes devices and methods for detecting and measuring the amount of acetaminophen-protein adducts in a sample.11-29-2012
20120094309NON-PROTEOLYTIC METHOD FOR THE DETERMINATION OF ANALYTES IN KERATINIZED STRUCTURES - Methods that permit the rapid release of one or more analytes from head or body hair or other keratinized structures of an individual (who may previously have ingested one or more of the analytes) are provided. The methods can include contacting the keratinized structure with a reducing agent but not with a proteolytic agent. The methods can further include identification and quantification of the one or more analytes by known analytical techniques such as immunoassays. The described methods do not damage the analyte and do not cause harmful effects on a subsequently-used analyte detection probe (e.g., an antibody).04-19-2012

Patent applications in class Assay in which an enzyme present is a label

Patent applications in all subclasses Assay in which an enzyme present is a label